Replies to post #189236 on Biotech Values

[GrthzGd]

I think GNFT.PA's problem with the P2b results is that pretty much all of the NASH 3--in both control and GFT505 arms--must have been mostly erased (maybe 57% for both arms?), thus nullifying any meaningful results for all lower severity patients. Clearly that's why they stressed in the CC that P3 will focus on NASH 4 and up patients, as this should enable them to distinguish the drug's signal from the placebo noise.